Originally published as JCO Early Release 10.1200/JCO.2005.03.070 on August 8 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fournel, P. Articles by Pérol, M. Search for Related Content PubMed PubMed Citation Articles by Fournel, P. Articles by Pérol, M. Related Articles Related Editorial Social Bookmarking                            What's this?

Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study

From the University Hospital, Saint-Etienne; University Hospital, Brest; Sainte-Marguerite University Hospital, Marseille; Lyon-Sud University Hospital; Croix-Rousse University Hospital, Lyon; University Hospital, Rennes; University Hospital, Limoges; General Hospital, Périgueux; General Hospital, Aix en Provence; General Hospital, Tarbes; Polyclinique du Bois, Lille; Clinical Research University Institute, Montpellier; GLOT (Groupe Lyon-Saint-Etienne d'Oncologie Thoracique); GFPC (Groupe Français de Pneumo-Cancérologie), France

Address reprint requests to Pierre Fournel, MD, Department of Pneumology, N Hospital, 42055 Saint-Etienne Cedex 2, France; e-mail: pierre.fournel{at}chu-st-etienne.fr

PURPOSE: We conducted a phase III study to compare the survival impact of concurrent versus sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage III non–small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: Patients were randomly assigned to one of the two treatment arms. In the sequential arm, patients received induction CT with cisplatin (120 mg/m²) on days 1, 29, and 57, and vinorelbine (30 mg/m²/wk) from day 1 to day 78, followed by thoracic RT at a dose of 66 Gy in 33 fractions (2 Gy per fraction and 5 fractions per week). In the concurrent arm, the same RT was started on day 1 with two concurrent cycles of cisplatin 20 mg/m²/d and etoposide 50 mg/m²/d (days 1 to 5 and days 29 to 33); patients then received consolidation therapy with cisplatin 80 mg/m² on days 78 and 106 and vinorelbine 30 mg/m²/wk from days 78 to 127.

RESULTS: Two hundred five patients were randomly assigned. Pretreatment characteristics were well balanced between the two arms. There were six toxic deaths in the sequential arm and 10 in the concurrent arm. Median survival was 14.5 months in the sequential arm and 16.3 months in the concurrent arm (log-rank test P = .24). Two-, 3-, and 4-year survival rates were better in the concurrent arm (39%, 25%, and 21%, respectively) than in the sequential arm (26%, 19%, and 14%, respectively). Esophageal toxicity was significantly more frequent in the concurrent arm than in the sequential arm (32% v 3%).

CONCLUSION: Although not statistically significant, clinically important differences in the median, 2-, 3-, and 4-year survival rates were observed, with a trend in favor of concurrent chemoradiation therapy, suggesting that is the optimal strategy for patients with locally advanced NSCLC.

Supported by a grant from Pierre Fabre Institute of Oncology, Boulogne, France.

Presented in part at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Will Future Progress in Non–Small-Cell Lung Cancer Be Step by Step ... or by Leaps and Bounds?
  Benjamin Movsas
  JCO 2005 23: 5859-5861 [Full Text]

This article has been cited by other articles:

				D. D. Ruysscher, A. Botterweck, M. Dirx, M. Pijls-Johannesma, R. Wanders, M. Hochstenbag, A.-M. C. Dingemans, G. Bootsma, W. Geraedts, J. Simons, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study Ann. Onc., January 1, 2009; 20(1): 98 - 102. [Abstract] [Full Text] [PDF]

				N. Hanna, M. Neubauer, C. Yiannoutsos, R. McGarry, J. Arseneau, R. Ansari, C. Reynolds, R. Govindan, A. Melnyk, W. Fisher, et al. Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology J. Clin. Oncol., December 10, 2008; 26(35): 5755 - 5760. [Abstract] [Full Text] [PDF]

				J. E. Bauman, M. S. Mulligan, R. G. Martins, B. F. Kurland, K. D. Eaton, and D. E. Wood Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Ann. Thorac. Surg., November 1, 2008; 86(5): 1632 - 1639. [Abstract] [Full Text] [PDF]

				M. A. Socinski, A. W. Blackstock, J. A. Bogart, X. Wang, M. Munley, J. Rosenman, L. Gu, G. A. Masters, P. Ungaro, A. Sleeper, et al. Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non-Small-Cell Lung Cancer: CALGB 30105 J. Clin. Oncol., May 20, 2008; 26(15): 2457 - 2463. [Abstract] [Full Text] [PDF]

				N. Pourel, N. Santelmo, N. Naafa, A. Serre, W. Hilgers, L. Mineur, N. Molinari, and F. Reboul Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 829 - 836. [Abstract] [Full Text] [PDF]

				P. A. Kosmidis, H. P. Kalofonos, C. Christodoulou, K. Syrigos, T. Makatsoris, D. Skarlos, C. Bakogiannis, C. Nicolaides, D. Bafaloukos, A. Bamias, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group Ann. Onc., January 1, 2008; 19(1): 115 - 122. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones and P. Hoskin Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm? J. Clin. Oncol., November 20, 2007; 25(33): 5281 - 5286. [Abstract] [Full Text] [PDF]

				A. W. Blackstock and R. Govindan Definitive Chemoradiation for the Treatment of Locally Advanced Non Small-Cell Lung Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4146 - 4152. [Abstract] [Full Text] [PDF]

				J. R. Jett, S. E. Schild, R. L. Keith, and K. A. Kesler Treatment of Non-small Cell Lung Cancer, Stage IIIB: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 266S - 276S. [Abstract] [Full Text] [PDF]

				D De Ruysscher, C Dehing, R-H Bremer, S. Bentzen, F Koppe, M Pijls-Johannesma, L Harzee, A Minken, R Wanders, M Hochstenbag, et al. Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients Ann. Onc., May 1, 2007; 18(5): 909 - 916. [Abstract] [Full Text] [PDF]

				I. Sekine, M. Sumi, Y. Ito, T. Kato, Y. Fujisaka, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., April 23, 2007; (2007) hym008v1. [Abstract] [Full Text] [PDF]

				X. S. Wang, D. L. Fairclough, Z. Liao, R. Komaki, J. Y. Chang, G. M. Mobley, and C. S. Cleeland Longitudinal Study of the Relationship Between Chemoradiation Therapy for Non-Small-Cell Lung Cancer and Patient Symptoms J. Clin. Oncol., September 20, 2006; 24(27): 4485 - 4491. [Abstract] [Full Text] [PDF]

				A. Vergnenegre, C. Combescure, P. Fournel, S. Bayle, C. Gimenez, P. J. Souquet, H. Lena, M. Perol, J. Y. Delhoume, and GFPC (Groupe Francais de Pneumo-Cancerologie) Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01) Ann. Onc., August 1, 2006; 17(8): 1269 - 1274. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Oncologist, July 1, 2006; 11(7): 809 - 823. [Abstract] [Full Text] [PDF]

				B. Movsas Will Future Progress in Non-Small-Cell Lung Cancer Be Step by Step ... or by Leaps and Bounds? J. Clin. Oncol., September 1, 2005; 23(25): 5859 - 5861. [Full Text] [PDF]